Our understanding of the pathophysiology of unstable angina (UA) and non—ST‐segment
elevation (NSTE) myocardial infarction (MI)[commonly referred to as NSTE acute coronary …

Advances in the management of patients with acute coronary syndromes (ACS) have
evolved dramatically over the past decade and, in many respects, represent a rapidly …

ACOanticoagulación oralACVCAssociation for Acute Cardiovascular CareAHAAmerican
Heart AssociationARC-HBRAcademic Research Consortium for High Bleeding …

Antithrombotic therapy is an essential component in the optimisation of clinical outcomes in
patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous …

Antithrombotic therapy represents the cornerstone of the pharmacological treatment in
patients with acute coronary syndrome (ACS). The optimal combination and duration of …

Acute coronary syndromes (ACS) include unstable angina (UA), non-ST-elevation
myocardial infarction (NSTEMI), and ST-elevation MI (STEMI). Each year in the US …

Acute coronary syndrome is a major health problem affecting approximately 1.5 million
individuals a year. Early diagnosis and appropriate evidence-based therapies improve …

Background: In the management of non-ST-elevation acute coronary syndrome (NSTACS) a
gap between guideline-recommended care and actual practice has been reported. A …

Dear Colleagues, In this EMCREG-International Monograph, Continuum of Care for Acute
Coronary Syndrome: Optimizing Treatment for STEMI and NSTEACS, you will find a detailed …

In randomized clinical trials enoxaparin in non ST-elevation acute coronary syndromes
(NSTE-ACS) has been shown to be more effective than unfractionated heparin in preventing …